Publications by authors named "Barry Keith"

Claim this Profile
C
Community-Based Recreation Therapy and Mental Health Recovery: A Mixed-Media Participatory Action Research Study.
Jessica J Ariss, Alison Gerlach, J B Baker, Keith Barry, Lyn Cooper

Prog Community Health Partnersh· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
Kirk L Stevens, Krystal J Alligood, Jennifer G Badiang Alberti, Thomas R Caferro, Stanley D Chamberlain, Barry R Keith

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases.
Edgar R Wood, Lisa M Shewchuk, Byron Ellis, Perry Brignola, Ronald L Brashear, Barry Keith

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Gottfried E Konecny, Mark D Pegram, Natarajan Venkatesan, Richard Finn, Guorong Yang, Barry R Keith

Cancer Res· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.
James G Conway, Brad McDonald, Janet Parham, Barry Keith, David W Rusnak

Proc Natl Acad Sci U S A· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
Micheal D Gaul, Yu Guo, Karen Affleck, G Stuart Cockerill, Tona M Gilmer, Barry R Keith

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Wenle Xia, Robert J Mullin, Barry R Keith, Lei-Hua Liu, Hong Ma

Oncogene· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis